Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Renal Insufficiency 1Malignant Tumor of Ill-defined Site 1Lung Neoplasms 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Dexamethasone 2melflufen 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1dabrafenib 1belinostat 1auricularum 1Thalidomide 1Pharmacogenomic Testing 1Lenalidomide 1L-melphalanyl-p-L-fluorophenylalanine ethyl ester 1Cyclophosphamide 1Calcium Dobesilate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Renal Insufficiency × Pharmacogenomic Testing × Clear all
NCT01907802 2018-08-14

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Terminated
8 enrolled

Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡